Early Mortality with Bispecific Antibody Therapy in RRMM: An IMWG Immunotherapy Database Real-World Analysis - PubMed
4 hours ago
- #multiple myeloma
- #early mortality
- #bispecific antibodies
- Bispecific antibody therapies (bsAbs) have improved outcomes for relapsed/refractory multiple myeloma (RRMM) patients.
- Early mortality (EM), defined as death within 12 months of therapy initiation, occurred in 34% of patients (148 out of 441).
- Median time from bsAb initiation to death was 2.87 months (IQR 1.38-6.85).
- Progressive disease was the leading cause of EM (72%), followed by infection (13%).
- 82% of patients had active disease at the time of death, regardless of the cause.
- Despite efficacy, EM remains high, highlighting the need for better disease control and supportive care.